CompanyGraph
Jazz Pharmaceuticals plc
JAZZ · Ireland
Turns cannabis grown in the UK into the only FDA-approved seizure medicine for two rare childhood epilepsy conditions.
Jazz Pharmaceuticals turns pharmaceutical-grade cannabidiol, grown and extracted at GW Pharmaceuticals' UK facilities under MHRA oversight, into Epidiolex — the only FDA-approved oral treatment for Dravet and Lennox-Gastaut syndrome in children. Because cannabidiol is a DEA Schedule V controlled substance, the volume that can legally enter US commerce each year is set by a federal quota allocated specifically to Jazz's licensed facilities, so even if the UK fields are producing at full capacity, the number of patients who can be supplied is capped by a DEA review cycle that no amount of investment can speed up. The same logic locks in the sodium oxybate drugs Xyrem and Xywav: generics exist, but because distribution requires every prescribing doctor and patient to enrol in a company-controlled REMS network, those generics cannot reach patients through a regular pharmacy. The one thing that would unwind all of this at once is a change in US federal cannabis policy — if cannabidiol is moved out of Schedule V, the quota architecture that makes the UK cultivation chain exclusively valuable disappears, and the decade-long sequence of licences and trials that no competitor has yet replicated would no longer need to be replicated.
How does this company make money?
Jazz earns money each time a unit of Epidiolex is sold through specialized rare-disease pharmacy networks, priced at orphan drug rates because the conditions it treats are so uncommon. Xyrem and Xywav generate revenue through the REMS distribution system, where the controlled-substance restrictions support premium pricing. The company also sells Zepzelca and Vyxeos directly to hospital systems under specialty pharmaceutical contracts for cancer treatment.
What makes this company hard to replace?
Doctors who prescribe Xyrem or Xywav must register in a company-controlled REMS program, and their patients must enroll in it too. Even if a generic version of sodium oxybate exists, it cannot be dispensed through a regular pharmacy under the current rules — so switching is not a matter of patient or doctor preference. For Epidiolex, pediatric neurologists follow specific dosing protocols built around this drug for Dravet syndrome and Lennox-Gastaut syndrome, and no other cannabidiol formulation has FDA approval for those exact conditions.
What limits this company?
The DEA sets an annual cap on how much cannabidiol and sodium oxybate Jazz can produce. That cap cannot be raised just by building more facilities or spending more money — the company has to go through a federal review cycle to get a higher quota. So even if demand grows and the factories are ready, supply cannot increase until the government approves it.
What does this company depend on?
Jazz cannot operate without five named inputs: the DEA manufacturing licences for both Schedule III sodium oxybate and Schedule V cannabidiol; GW Pharmaceuticals' UK cannabis cultivation facilities, which are the only approved source of the cannabidiol that goes into Epidiolex; the FDA's REMS distribution network that controls who can prescribe and receive Xyrem and Xywav; the EMA's marketing authorization that allows cannabinoid product sales in Europe; and specialized pediatric neurology treatment centers that administer Epidiolex.
Who depends on this company?
Pediatric epilepsy specialists treating children with Dravet syndrome and Lennox-Gastaut syndrome would lose access to the only FDA-approved cannabidiol formulation if Epidiolex supply were disrupted. Narcolepsy patients enrolled in the Xyrem and Xywav REMS program cannot simply switch to a generic at a regular pharmacy — the distribution system does not allow it. Oncology treatment centers using Zepzelca for second-line small cell lung cancer would also be affected, because there are very few alternative sources of lurbinectedin.
How does this company scale?
Production of Epidiolex and Xyrem and Xywav can grow if the DEA grants higher quota allocations and if Jazz expands output at its existing licensed facilities — both of which are possible but neither of which is fast. What cannot be sped up at all, regardless of money spent, is getting a new rare-disease indication approved: clinical trials in small pediatric patient populations must run sequentially, and FDA review follows after. Capital cannot compress that timeline.
What external forces can significantly affect this company?
The biggest external threat is a change in US federal cannabis policy: if cannabidiol is rescheduled out of Schedule V, the legal structure that protects Jazz's market position changes fundamentally. In Europe, EU regulations on orphan drug pricing affect how much Jazz can charge for its rare epilepsy treatments and how much governments will reimburse. Changes to Irish corporate tax policy could also affect Jazz's costs, since the company is headquartered in Dublin.
Where is this company structurally vulnerable?
If the US federal government reclassifies cannabidiol out of Schedule V, the DEA quota system that currently blocks other manufacturers disappears. At that point, any company with pharmaceutical-grade cannabidiol could apply for the same FDA approval without needing to replicate the quota, the UK cultivation chain, or the licence sequence that currently keeps competitors out.